High accumulation of tilianin in in-vitro cultures of Agastache mexicana and its potential vasorelaxant action

Tilianin content and morphological characterization of colchicine-induced autotetraploids in Agastache mexicana

Background

Agastache mexicana Linton & Epling subsp. mexicana (Lamiaceae) is an aromatic medicinal plant, characterized by a high concentration of tilianin, a flavonoid with therapeutic potential in cardiovascular diseases. In this study, we have explored the use of colchicine to obtain autotetraploid lines of A. mexicana and analyze their morphological characteristics. In addition, we aimed to identify polyploid plants with a high content of tilianin.

Methods

In vitro seedlings at the stage of cotyledon emergence were dipped in colchicine solution at 0.0%, 0.1%, 0.3%, and 0.5% (w/v) for 6, 12, and 24 h. Seedlings were cultured on half-strength basal Murashige and Skoog medium supplemented with 20 g/L sucrose. After 2 months, the shoots from surviving seedlings were excised and grown individually in the same medium to obtain plantlets. The ploidy level of all materials was verified through flow cytometry and chromosome counting before acclimatization and transfer to the greenhouse. The investigated characteristics included length, density and stomatal index, leaf area, chlorophyll content, flower size and color, and tilianin content measured by high-performance liquid chromatography.

Results

The most efficient production of tetraploid in terms of percentage was achieved with 0.1% colchicine for 6 h resulting in no generation of mixoploids. Tetraploid plants had twice the number of chromosomes (2n = 4x = 36) and nearly twice the total DNA content (2.660 ± 0.236 pg) of diploids. Most tetraploid A. mexicana plants showed variations in flower and leaf characteristics compared to the diploid controls. High-performance liquid chromatography analysis showed that tetraploid plants with small leaves produced the greatest amount of tilianin; up to 32.964 ± 0.004 mg/g dry weight (DW), compared to diploid plants with 6.388 ± 0.005 mg/g DW.

Conclusion

In vitro polyploidization using colchicine demonstrates potential for enhancing bioactive constituents of A. mexicana. This approach has proven effective in generating elite tetraploid lines with increased tilianin production.

Agastache Species: A Comprehensive Review on Phytochemical Composition and Therapeutic Properties

The Agastache genus is part of the Lamiaceae family and is native to North America, while one species, Agastache rugosa (A. rugosa), is native to East Asia. A review on the phytochemistry and bioactivity of Agastache genus was last performed in 2014. Since then, a lot of progress has been made on the characterization of the phytochemical and pharmacological profiles of Agastache species. Thus, the purpose of this paper is to present a summary of the findings on the phytochemistry and biological effects of several Agastache species, including both extracts and essential oil characterization. We performed a comprehensive search using PubMed and Scopus databases, following PRISMA criteria regarding the study selection process. The available data is focused mainly on the description of the chemical composition and bioactivity of A. rugosa, with fewer reports referring to Agastache mexicana (A. mexicana) and Agastache foeniculum (A. foeniculum). Agastache species are characterized by the dominance of flavonoids and phenolic acids, as well as volatile compounds, particularly phenylpropanoids and monoterpenes. Moreover, a series of pharmacological effects, including antioxidant, cytotoxic, antimicrobial, anti-atherosclerotic, and cardioprotective properties, have been reported for species from the Agastache genus.

Therapeutic application of natural products: NAD+ metabolism as potential target

BACKGROUND

Nicotinamide adenine dinucleotide (NAD⁺) metabolism is involved in the entire physiopathological process and is critical to human health. Long-term imbalance in NAD⁺ homeostasis is associated with various diseases, including non-alcoholic fatty liver disease, diabetes mellitus, cardiovascular diseases, neurodegenerative disorders, aging, and cancer, making it a potential target for effective therapeutic strategies. Currently, several natural products that target NAD⁺ metabolism have been widely reported to have significant therapeutic effects, but systematic summaries are lacking.

PURPOSE

To summarize the latest findings on the prevention and treatment of various diseases through the regulation of NAD⁺ metabolism by various natural products in vivo and in vitro models, and evaluate the toxicities of the natural products.

METHODS

PubMed, Web of Science, and ScienceDirect were searched using the keywords "natural products sources," "toxicology," "NAD⁺ clinical trials," and "NAD⁺," and/or paired with "natural products" and "diseases" for studies published within the last decade until January 2023.

RESULTS

We found that the natural products mainly include phenols (curcumin, cyclocurcumin, 4-hydroxybenzyl alcohol, salvianolic acid B, pterostilbene, EGCG), flavonoids (pinostrobin, apigenin, acacetin, tilianin, kaempferol, quercetin, isoliquiritigenin, luteolin, silybin, hydroxysafflor yellow A, scutellarin), glycosides (salidroside), quinones (emodin, embelin, β-LAPachone, shikonin), terpenoids (notoginsenoside R1, ginsenoside F2, ginsenoside Rd, ginsenoside Rb1, ginsenoside Rg3, thymoquinone, genipin), pyrazines (tetramethylpyrazine), alkaloids (evodiamine, berberine), and phenylpropanoids (ferulic acid). These natural products have antioxidant, energy-producing, anti-inflammatory, anti-apoptotic and anti-aging effects, which mainly influence the NAMPT/NAD⁺/SIRT, AMPK/SIRT1/PGC-1α, Nrf2/HO-1, PKCs/PARPs/NF-κB, and AMPK/Nrf2/mTOR signaling pathways, thereby regulating NAD⁺ metabolism to prevent and treat various diseases. These natural products have been shown to be safe, tolerable and have fewer adverse effects in various in vivo and in vitro studies and clinical trials.

CONCLUSION

We evaluated the toxic effects of natural products and summarized the available clinical trials on NAD⁺ metabolism, as well as the recent advances in the therapeutic application of natural products targeting NAD⁺ metabolism, with the aim to provide new insights into the treatment of multiple disorders.

Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders

Cardiovascular disorders (CVDs) are the leading risk factor for death worldwide, and research into the processes and treatment regimens has received a lot of attention. Tilianin is a flavonoid glycoside that can be found in a wide range of medicinal plants and is most commonly obtained from Dracocephalum moldavica. Due to its extensive range of biological actions, it has become a well-known molecule in recent years. In particular, numerous studies have shown that tilianin has cardioprotective properties against CVDs. Hence, this review summarises tilianin's preclinical research in CVDs, as well as its mechanism of action and opportunities in future drug development. The physicochemical and drug-likeness properties, as well as the toxicity profile, were also highlighted. Tilianin can be a natural lead molecule in the therapy of CVDs such as coronary heart disease, angina pectoris, hypertension, and myocardial ischemia, according to scientific evidence. Free radical scavenging, inflammation control, mitochondrial function regulation, and related signalling pathways are all thought to play a role in tilianin's cardioprotective actions. Finally, we discuss tilianin-derived compounds, as well as the limitations and opportunities of using tilianin as a lead molecule in drug development for CVDs. Overall, the scientific evidence presented in this review supports that tilianin and its derivatives could be used as a lead molecule in CVD drug development initiatives.

A Systematic Approach to Agastache mexicana Research: Biology, Agronomy, Phytochemistry, and Bioactivity

Mexico is the center of origin of the species popularly known as toronjil or lemon balm (Agastache mexicana Linton & Epling). Two subspecies have been identified and are commonly called purple or red (Agastache mexicana Linton & Epling subspecies. mexicana) and white (Agastache mexicana subspecies xolocotziana Bye, E.L. Linares & Ramamoorthy). Plants from these subspecies differ in the size and form of inflorescence and leaves. They also possess differences in their chemical compositions, including volatile compounds. Traditional Mexican medicine employs both subspecies. A. mexicana exhibits a broad range of pharmacological properties, such as anti-inflammatory, anxiolytic, and antioxidant. A systematic vision of these plant’s properties is discussed in this review, exposing its significant potential as a source of valuable bioactive compounds. Furthermore, this review provides an understanding of the elements that make up the species’ holistic system to benefit from lemon balm sustainably.

Mexican Plants and Derivates Compounds as Alternative for Inflammatory and Neuropathic Pain Treatment-A Review

Despite the availability of many anti-pain drugs, in the form of NSAIDs, steroids, gabapentinoids, opioids, and antidepressants, in this study we address the natural compounds belonging to the group of Mexican medicinal plants or "Mexican folk medicine", used for pain management in Mexico. Our interest in this subject is due to the growing idea that "natural is harmless" and to the large number of side effects exhibited in pharmacotherapy. The objective of this review was to document the scientific evidence about Mexican medicinal plants and their derivatives used for inflammatory and neuropathic pain treatment, as well as the mechanisms of action implicated in their antinociceptive effects, their possible adverse effects, and the main pharmacological aspects of each plant or compound. Our data review suggested that most studies on Mexican medicinal plants have used inflammatory experimental models for testing. The anti-pain properties exerted by medicinal plants lack adverse effects, and their toxicological assays report that they are safe to consume; therefore, more studies should be performed on preclinical neuropathic pain models. Moreover, there is no convincing evidence about the possible mechanisms of action involved in the anti-pain properties exerted by Mexican plants. Therefore, the isolation and pharmacological characterization of these plant derivatives' compounds will be important in the design of future preclinical studies.

Improved oral delivery of tilianin through lipid-polymer hybrid nanoparticles to enhance bioavailability

Tilianin (TIL) may prevent and treat myocardial ischemia reperfusion injuries. However, its oral administration is hampered by its low bioavailability. The present study aimed to formulate lipid-polymer hybrid nanoparticles (LPHNs) as carriers for the sustained release and oral bioavailability enhancement of TIL in vitro and in vivo. A nanodrug delivery system of TIL-loaded LPHNs (TIL-LPHNs) was constructed. TIL-LPHNs were prepared via a self-assembly method, and their particle size, polymer dispersity index (PDI), zeta potential, encapsulation efficiency (EE) and morphology were investigated. In addition, pharmacokinetic studies were performed in vivo. The TIL-LPHN formulation produced a spherical, homogeneous, smooth surface and multi-lamellar structured nanoparticles. The particle size and distribution profile of TIL-LPHNs had a mean particle diameter of 54.6 ± 5.3 nm and PDI of 0.112 ± 0.017. The zeta potential was -33.4 ± 4.7 mV. The EE of TIL-LPHNs was 86.6 ± 3.6%, which was determined with the dialysis method. The TIL-LPHNs significantly enhanced the oral bioavailability of TIL with a 3.7-fold increase in the area under the concentration-time curve in comparison with the TIL solution. These findings support the potential use of LPHNs in improving the stability and bioavailability of TIL via oral administration.